KATELYN ELY: Open Payments
NPI 1770136574 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,381 in 60 payments from 15 companies in 2025. Trend: 2023 $1,582 · 2024 $2,867 · 2025 $1,381
Food & beverage: $1,298Education: $83
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $280 |
| Galderma Laboratories, L.P. | 9 | $238 |
| Regeneron Healthcare Solutions, Inc. | 3 | $161 |
| Janssen Biotech, Inc. | 5 | $142 |
| Novartis Pharmaceuticals Corporation | 3 | $84 |
| Amgen Inc. | 4 | $78 |
| Arcutis Biotherapeutics, Inc. | 4 | $76 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 4 | $73 |
| GENZYME CORPORATION | 2 | $64 |
| Almirall LLC | 2 | $56 |
Products named: DUPIXENT, NEMLUVIO, SKYRIZI, TREMFYA, OTEZLA, Zoryve, RINVOQ, Seysara.
Industry payments across GA — which companies pay providers there.
